Drugs in MeSH Category Astringents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	217074-002	Aug 22, 2023	AP	RX	No	No
Aspiro	ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	219585-001	May 1, 2025	AP	RX	No	No
Am Regent	ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	209377-002	Jul 18, 2019	AP	RX	Yes	Yes
Abraxis Pharm	ZINC SULFATE	zinc sulfate	INJECTABLE;INJECTION	019229-002	May 5, 1987		DISCN	No	No
Nivagen Pharms Inc	ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	214597-002	Jul 5, 2024	AP	RX	No	No
Nivagen Pharms Inc	ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	214597-001	Jul 5, 2024	AP	RX	No	No
Apotex	ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	218059-001	Jun 10, 2024	AP	RX	No	No

Astringents Market Analysis and Financial Projection

The astringent drug market and its patent landscape are evolving dynamically, driven by advancements in formulation technologies, expanding therapeutic applications, and shifting consumer preferences towards natural ingredients. Here's a detailed analysis:

---

Market Dynamics

Growth Projections and Segments

• The global astringent market is projected to grow at a CAGR of 8.4% (2025–2031), with demand fueled by rising adoption in skincare, surgical procedures, and industrial applications like water treatment and leather tanning[1][14].
• Segments by product type:
  • Chemical astringents (e.g., aluminum acetate) dominate medical use for wound care[6].
  • Natural/herbal astringents (witch hazel, tea tree oil) are gaining traction in cosmetics due to eco-friendly trends[17].
• Key end-users: Hospitals, surgical centers, and cosmetics/pharmaceutical industries[1][6].

Drivers and Opportunities

• Skincare demand: Rising consumer focus on acne treatment and oily skin management[6][17].
• Technological innovations:
  • Natural ingredient integration (e.g., seaweed-based formulations for hydration + pore-tightening)[1].
  • AI-driven personalization for tailored skincare solutions[1].
• Sustainability: Ethically sourced raw materials and eco-friendly production methods[1].

Challenges

• Irritation risks: High alcohol content in traditional formulations[7].
• Regulatory scrutiny: Ensuring safety and efficacy in medical-grade products[6].

---

Patent Landscape

Key Trends

• Cosmetic formulations:
  • L’Oréal’s US8974804: Oil-in-water emulsion with elastomeric silicones for stabilized delivery[2].
  • Avon’s US8815265: Anti-aging sulfonyloxybenzylamines targeting biochemical pathways[2].
• Therapeutic diversification:
  • Anti-inflammatory patents: Polyphenols (e.g., strictinin) for allergy and eczema treatments[2].
  • Hydrogel composites: Laponite-based systems to reduce burst drug release[5].

Innovation Focus

• Delivery systems: Patents emphasize controlled-release mechanisms (e.g., gel matrices, emulsions) to enhance efficacy[2][5].
• Natural actives: Plant-derived compounds (witch hazel, green tea) replace synthetic agents[2][6].

Classification and Search

• MeSH integration: Astringents are classified under D001252 (Agents causing tissue contraction)[16].
• Challenges in patent retrieval: Structural differences between MeSH and International Patent Classification (IPC) hinder cross-referencing[13].

---

Competitive Landscape

• Major players: L’Oréal, Avon, Beiersdorf, and Achieve Life Sciences (novel salt formulations like cytisinicline succinate)[2][4].
• Strategic moves: Mergers, sustainability initiatives, and R&D investments in natural/organic products[1][14].

---

Future Outlook

• Personalized medicine: AI-driven formulations for specific skin types[1].
• Expansion into emerging markets: Asia-Pacific’s growing middle class and healthcare infrastructure[6][17].

Highlight: “Natural and organic astringents are transforming skincare, merging efficacy with sustainability”—The Insight Partners[1].

---

This market’s growth hinges on balancing innovation with safety, while patents reflect a shift toward multifunctional, eco-conscious solutions. Integration of MeSH classifications in patent databases could further streamline research and development[10][11].

References

1. https://www.theinsightpartners.com/reports/astringent-professional-market
2. https://patents.justia.com/patents-by-us-classification/514/848
3. https://www.uv.es/fhersan/EVES2013/NLM%20Classification/nlmclass/class_qv.html
4. https://www.biospace.com/achieve-announces-patent-granted-in-the-u-s-for-novel-formulation-of-cytisinicline
5. https://mdpi-res.com/bookfiles/book/8707/Feature_Reviews_in_Pharmaceutical_Technology.pdf?v=1741831696
6. https://sites.google.com/view/focused-insights/us-astringent-market-by-type
7. https://patents.google.com/patent/US6482446B2/en
8. https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0452_Pheburane_CL_Report.pdf
9. https://www.youtube.com/watch?v=o6CTfdx85ys
10. https://pubmed.ncbi.nlm.nih.gov/20865561/
11. https://ceur-ws.org/Vol-2032/om2017_Tpaper4.pdf
12. https://www.nlm.nih.gov/pubs/techbull/nd24/nd24_annual_mesh_processing.html
13. https://pubmed.ncbi.nlm.nih.gov/23734562/
14. https://www.marketresearchfuture.com/reports/astringent-professional-market-40090
15. https://pubmed.ncbi.nlm.nih.gov/10857475/
16. https://meshb.nlm.nih.gov/record/ui?ui=D001252
17. https://github.com/marlanamarvn/Market-Research-Report-List-1/blob/main/astringent-market.md

Last updated: 2025-03-24